225 Thousand compounds in stock
Original and unique
210 Million novel building blocks
Over 650 highly skillful chemists
Unique synthesis technologies
14 Billion REAL compounds and
Custom Library Synthesis
On site access to all Enamine stock BB’s
Highly flexible arrangements
2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from December 2020
24 February 2021
A new multi-year drug discovery agreement will focus on CNS drug discovery
Kyiv, Ukraine, February 24 2021 - Enamine Ltd. a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments and screening compounds announced today that it has extended its long-standing research collaboration with Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company specialized in allosteric modulation-based drug discovery and development. Enamine is providing Addex with its integrated capability in medicinal chemistry, pharmacology and ADME/PK (Absorption, Distribution, Metabolism, Excretion/Pharmacokinetics) to efficiently support Addex’ small molecule CNS drug discovery programs.
Read press release
15 January 2021
We have several Postdoc positions in organic chemistry to work at Enamine Ltd. (Ukraine, Kyiv) on a ERC-project “Saturated bioisosteres of benzene.” Start: 1 April 2021 (or later).
Please, send the application documents (motivation letter, CV, list of publications, recommendation letters) to Pavel.MykhailiukATmail.enamine.net
11 December 2020
Congratulations to Pavel Mykhailiuk, Chief Scientific Officer at Enamine, for receiving ERC Consolidator Grant funding for the Project: BENOVELTY - Saturated bioisosteres of benzene and their application in drug design.
The research will be carried out at Enamine Ltd in Ukraine, a global provider of chemical and biological services to biotech companies, academic institutions and research organisations.
Dvl-Axin Inhibitors library
Dvl-Axin interaction is mediated by specific PDZ-domain. Since structural information on this PPI interface is not available, we built a respective homology using the reported amino acid sequence and numerous SBio data on PDZ domains. The resulting model was used to conduct docking of our drug-like collection of small molecules at Enamine (2 776 742 compounds) and prioritize the best ‘hits’ using rigorous internal medchem filters to yield ca. 2 559 final Dvl-biased compounds. A representative example of putative Dvl binder is shown below.
Fig. 1.A representative example of Dvl/PDZ-domain binding ligand from our focused set.